We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App




Siemens Partners with Hamamatsu to Expand Into Digital Pathology in Americas and Europe

By LabMedica International staff writers
Posted on 09 Mar 2023
Print article
Image: In the US, C13220-01MD NanoZoomer S360MD Slide scanner system is intended for in vitro diagnostic use (Photo courtesy of Hamamatsu)
Image: In the US, C13220-01MD NanoZoomer S360MD Slide scanner system is intended for in vitro diagnostic use (Photo courtesy of Hamamatsu)

Today, digital pathology is at a tipping point, with the evolution from glass to digital already transforming standards of care. This transformation is being driven by the technological combination of high-speed, high-resolution imaging; trusted medical data storage; fast, secure data transmission; and intuitive, inter-operable workflows with continual improvements in AI.

Siemens Healthineers (Erlangen, Germany) has entered into a multi-year distribution agreement with Hamamatsu (Shizuoka, Japan), under which Hamamatsu will provide NanoZoomer whole slide scanners to support Siemens’ expansion into digital pathology in the Americas and Europe.

Hamamatsu, a leading manufacturer of photonics devices, including whole slide scanners for digital pathology, has more than 60 years of experience in photonics engineering. The company has developed NanoZoomer scanners which are renowned for their image quality, reliability, and ease of use. Siemens has decades of experience in diagnostics, enterprise imaging, and healthcare IT. The partnership with Hamamatsu NanoZoomer whole slide scanners will help Siemens close the gap between radiology and pathology to achieve full potential of digital operations in patient care.

"This partnership between Hamamatsu and Siemens Healthineers will create tremendous value for laboratories and healthcare ecosystems," said, Fumio Iwase, Executive Officer, Division Director, Systems Division at Hamamatsu Photonics K.K., who believes that integrating complex hardware and software solutions into pathologists' workflow is critical to maximizing the potential of digital pathology in clinical environments. "Together, we will help laboratories across healthcare systems adopt digital pathology by seamlessly integrating pathologists' workflow with hardware to provide the utmost patient care."

"We now complement our portfolio for digital pathology with the products and expertise of Hamamatsu," added Christian Zapf, Head of Digital & Automation at Siemens Healthineers. "Together with our strong Syngo Carbon portfolio in enterprise imaging IT, we can now help our customers to comprehensively gain the benefits of a digital transformation in digital pathology."

Related Links:
Siemens Healthineers 
Hamamatsu 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test
New
TRAb Immunoassay
Chorus TRAb

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.